Lifecore Biomedical, Inc. (LFCR)
NASDAQ:LFCR
Want to see LFCR full AI Analyst Report?
LFCR Stock Chart & Stats
$7.71
-$0.17(-2.79%)
At close: 4:00 PM EST
$7.71
-$0.17(-2.79%)
Day’s Range― - ―
52-Week Range$3.63 - $8.98
Previous CloseN/A
Volume140.23K
Average Volume (3M)196.82K
Market Cap
$211.93M
Enterprise Value$317.64M
Total Cash (Recent Filing)$20.80M
Total Debt (Recent Filing)$150.14M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding37,509,407
10 Day Avg. Volume200,376
30 Day Avg. Volume196,824
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)175.14
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.50
Enterprise Value/Revenue2.35
Enterprise Value/Gross Profit7.54
Enterprise Value/Ebitda-309.29
Forecast
1Y Price Target
$5.50Price Target Upside-28.66% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$122.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent positive operating and free cash flow provides a durable internal funding source to cover operating needs, service debt, and invest in capacity or R&D. This improves resilience during revenue cyclicality and reduces reliance on external financing over the medium term.
Specialized CDMO NicheA focused sterile injectable CDMO model with end-to-end formulation, aseptic fill-finish and analytical services creates high technical barriers to entry, long onboarding cycles, and sticky customer relationships, supporting recurring revenue and pricing power over time.
Talent/ Governance ContinuityApproval of a refreshed stock incentive plan and re-election of directors signals governance continuity and gives management a tool to attract and retain specialized talent. Stronger retention reduces operational risk in complex manufacturing and supports execution of multi-year customer programs.
Bears Say
High LeverageVery high debt relative to equity constrains financial flexibility, raises refinancing and interest-rate risk, and limits capacity to fund inorganic growth or withstand demand shocks. Elevated leverage amplifies downside in prolonged revenue weakness or margin pressure.
Persistent Net LossesSubstantial net losses and weak profitability despite improving cash flow indicate core earnings power remains unproven. Continued negative margins reduce retained earnings, impede equity rebuild, and make long-term reinvestment or dividend initiation unlikely until sustained profits appear.
Revenue Lumpiness / Utilization RiskRevenue and margins depend on lumpy contract manufacturing campaigns and capacity utilization, making topline and free cash flow volatile. This utilization sensitivity complicates forecasting, increases downside in demand troughs, and can leave fixed costs under-absorbed for extended periods.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical, Inc.’s price range in the past 12 months?
Lifecore Biomedical, Inc. lowest stock price was $3.63 and its highest was $8.98 in the past 12 months.
What is Lifecore Biomedical, Inc.’s market cap?
Lifecore Biomedical, Inc.’s market cap is $211.93M.
When is Lifecore Biomedical, Inc.’s upcoming earnings report date?
Lifecore Biomedical, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 53 days.
How were Lifecore Biomedical, Inc.’s earnings last quarter?
Currently, no data Available
Is Lifecore Biomedical, Inc. overvalued?
According to Wall Street analysts Lifecore Biomedical, Inc.’s price is currently Overvalued.
Does Lifecore Biomedical, Inc. pay dividends?
Lifecore Biomedical, Inc. does not currently pay dividends.
What is Lifecore Biomedical, Inc.’s EPS estimate?
Lifecore Biomedical, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Lifecore Biomedical, Inc. have?
Lifecore Biomedical, Inc. has 37,509,407 shares outstanding.
What happened to Lifecore Biomedical, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lifecore Biomedical, Inc.?
Currently, no hedge funds are holding shares in LFCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Company Description
Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc. (LFCR) operates as a multifaceted contract development and manufacturing organization (CDMO) with a global presence, conducting business through its various subsidiaries. The company's operations are divided into three core segments: Lifecore, Curation Foods, and Other. The Lifecore division is primarily responsible for the production of pharmaceutical-grade sodium hyaluronate (HA) in bulk quantities. It also handles the formulation and sterile filling of syringes and vials containing injectable medications used to treat diverse medical ailments and conditions. Beyond manufacturing, this segment provides a comprehensive suite of CDMO services to its partners. These include the development of new technologies and formulations, analytical method creation, oversight of material component modifications, execution of pilot and stability studies, validation of manufacturing processes, and the production of materials for clinical trials. This extensive support is offered for both HA-based and non-HA products that necessitate aseptic formulation and filling. Furthermore, the Lifecore segment markets its non-HA medical offerings mainly to the ophthalmic (eye care), orthopedic (bone and joint), and other specialized healthcare sectors. The Curation Foods segment focuses on the production, marketing, and distribution of food products. This includes olive oils and wine vinegars sold under the "O" brand, as well as guacamole and avocado-based items available under the "Yucatan" and "Cabo Fresh" brands, in addition to various private label agreements. Established in 1986, the company was formerly known as Landec Corporation before officially rebranding as Lifecore Biomedical, Inc. in November 2022. Its corporate headquarters are situated in Santa Maria, California.
LFCR Stock 12 Month Forecast
Average Price Target
$5.50
▼(-28.66% Downside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
17.06% Insiders
6.34% Mutual Funds
46.64% Other Institutional Investors
23.32% Public Companies and
Individual Investors